SK Life Science, Inc. Presents XCOPRI® (Cenobamate Tablets) CV Data At The AES 2024 Annual Meeting Showing A Deeper Understanding Of Cenobamate's Dual Mechanism Of Action
SK Life Science, Inc. Presents XCOPRI® (Cenobamate Tablets) CV Data At The AES 2024 Annual Meeting Showing A Deeper Understanding Of Cenobamate's Dual Mechanism Of Action . (MENAFN - PR Newswire) 
  
  
 
 
 PARAMUS, N.J., Dec. 8, 2024 /PRNewswire/ -- SK Life Science, Inc. , a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108969054/SK-Life-Science-Inc-Presents-XCOPRI-Cenobamate-Tablets-CV-Data-At-The-AES-2024-Annual-Meeting-Showing-A-Deeper-Understanding-Of-Cenobamates-Dual-Mechanism-Of-Action
2024-12-08
rss
(MENAFN - PR Newswire) 
  
  
 
 
 PARAMUS, N.J., Dec. 8, 2024 /PRNewswire/ -- SK Life Science, Inc. , a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK ...
SK Life Science, Inc. Presents XCOPRI® (Cenobamate Tablets) CV Data At The AES 2024 Annual Meeting Showing A Deeper Understanding Of Cenobamate's Dual Mechanism Of Action